<DOC>
	<DOCNO>NCT00766012</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability pharmacokinetics AZD2066 give multiple dos Japanese healthy male subject . Four ( 4 ) consecutive multiple-ascending panel plan . Subjects start initial single dose follow wash-out period 48 hour adequately define single-dose pharmacokinetics . For third forth dose panel , wash-out period extend 96 hour evaluate safety subject . Thereafter subject dose daily 10 day . Ten ( 10 ) subject allocate dose panel randomize receive either AZD2066 placebo .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetics After Multiple Doses AZD2066 Japanese Subjects</brief_title>
	<detailed_description>The purpose study investigate safety , tolerability pharmacokinetics AZD2066 give multiple dos Japanese healthy male subject . Four ( 4 ) consecutive multiple-ascending panel plan . Subjects start initial single dose follow wash-out period 48 hour adequately define single-dose pharmacokinetics . For third forth dose panel , wash-out period extend 96 hour evaluate safety subject . Thereafter subject dose daily 10 day . Furthermore , study expand include two additional panel increment dose multiple dose period ( 12 day ) order obtain sufficient information safety tolerability multiple dose AZD2066 Japanese subject higher level exposure . Ten ( 10 ) subject allocate dose panel randomize receive either AZD2066 placebo .</detailed_description>
	<criteria>Provision sign informed consent Healthy Japanese male judge investigator Clinically normal physical finding laboratory value judge investigator normal rest ECG . History somatic disease/condition , may interfere objective study , judge investigator . History previous ongoing psychiatric disease/condition include psychosis , affective disorder , anxiety disorder , borderline state personality disorder . Intake medicine ( except occasional paracetamol ) within first 2 week first administration study drug .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>AZD2066</keyword>
	<keyword>Japanese</keyword>
</DOC>